top esports games
Georgia QB Carson Beck takes hit on throwing arm before halftime, leaving status uncertainProceeds to be used primarily to acquire bitcoin and repurchase existing convertible notes due 2026 Fort Lauderdale, FL, Dec. 04, 2024 (GLOBE NEWSWIRE) -- MARA Holdings, Inc. (NASDAQ: MARA) (“MARA” or the “Company”), a global leader in leveraging digital asset compute to support the energy transformation, today announced the closing on December 4, 2024 of its offering of 0.00% convertible senior notes due 2031 (the “notes”). The aggregate principal amount of the notes sold in the offering was $850 million. MARA also granted the initial purchasers an option to purchase an additional $150 million aggregate principal amount of the notes within a 13-day period beginning on, and including, the date on which the notes were first issued. The notes were sold in a private offering to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The net proceeds from the sale of the notes were approximately $835.1 million, after deducting the initial purchasers’ discounts and commissions but before estimated offering expenses payable by MARA. MARA expects to use approximately $48 million of the net proceeds from the sale of the notes to repurchase approximately $51 million in aggregate principal amount of its existing convertible notes due 2026 (the “existing 2026 convertible notes”) in privately negotiated transactions with the remainder of the net proceeds to be used to acquire additional bitcoin and for general corporate purposes, which may include working capital, strategic acquisitions, expansion of existing assets, and repayment of additional debt and other outstanding obligations. The notes are unsecured, senior obligations of MARA. The notes will not bear regular interest and the principal amount of the notes will not accrete. MARA may pay special interest, if any, at its election as the sole remedy for failure to comply with its reporting obligations and under certain other circumstances, each pursuant to the indenture. Special interest, if any, on the notes will be payable semi-annually in arrears on June 1 and December 1 of each year, beginning on June 1, 2025 (if and to the extent that special interest is then payable on the notes). The notes will mature on June 1, 2031, unless earlier repurchased, redeemed or converted in accordance with their terms. Subject to certain conditions, on or after June 5, 2029, MARA may redeem for cash all or any portion of the notes at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid special interest, if any, to, but excluding, the redemption date, if the last reported sale price of MARA’s common stock has been at least 130% of the conversion price then in effect for a specified period of time ending on, and including, the trading day immediately before the date MARA provides the notice of redemption. If MARA redeems fewer than all the outstanding notes, at least $75 million aggregate principal amount of notes must be outstanding and not subject to redemption as of the relevant redemption notice date. Holders of notes may require MARA to repurchase for cash all or any portion of their notes on June 4, 2027 and on June 4, 2029 or upon the occurrence of certain events that constitute a fundamental change under the indenture governing the notes at a repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid special interest, if any, to, but excluding, the date of repurchase. In connection with certain corporate events or if MARA calls any note for redemption, it will, under certain circumstances, be required to increase the conversion rate for holders who elect to convert their notes in connection with such corporate event or notice of redemption. The notes are convertible into cash, shares of MARA’s common stock, or a combination of cash and shares of MARA’s common stock, at MARA’s election. Prior to March 1, 2031, the notes are convertible only upon the occurrence of certain events and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. The conversion rate for the notes is initially 28.9159 shares of MARA’s common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $34.5830 per share. The initial conversion price of the notes represents a premium of approximately 40.0% over the U.S. composite volume weighted average price of MARA’s common stock from 2:00 p.m. through 4:00 p.m. Eastern Daylight Time on Monday, December 2, 2024, which was $24.7022. The conversion rate is subject to adjustment upon the occurrence of certain events. In connection with any repurchase of the existing 2026 convertible notes, MARA expects that holders of the existing 2026 convertible notes who agree to have their notes repurchased and who have hedged their equity price risk with respect to such notes (the “hedged holders”) will unwind all or part of their hedge positions by buying MARA’s common stock and/or entering into or unwinding various derivative transactions with respect to MARA’s common stock. The amount of MARA’s common stock to be purchased by the hedged holders or in connection with such derivative transactions may be substantial in relation to the historic average daily trading volume of MARA’s common stock. This activity by the hedged holders could increase (or reduce the size of any decrease in) the market price of MARA’s common stock, including concurrently with the pricing of the notes, resulting in a higher effective conversion price of the notes. MARA cannot predict the magnitude of such market activity or the overall effect it will have on the price of the notes or MARA’s common stock. The notes were sold to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and the shares of MARA’s common stock issuable upon conversion of the notes, if any, have not been and will not be registered under the Securities Act or the securities laws of any other jurisdiction, and the notes and any such shares may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements. The offering of the notes was made only by means of a private offering memorandum. This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, the notes, nor shall there be any sale of the notes in any state or jurisdiction in which such offer, solicitation or sale would be unlawful under the securities laws of any such state or jurisdiction. Nothing in this press release shall be deemed an offer to purchase MARA’s existing 2026 convertible notes. About MARA MARA (NASDAQ:MARA) is a global leader in digital asset compute that develops and deploys innovative technologies to build a more sustainable and inclusive future. MARA secures the world’s preeminent blockchain ledger and supports the energy transformation by converting clean, stranded, or otherwise underutilized energy into economic value. Forward-Looking Statements Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to MARA’s use of the net proceeds of the offering. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the factors discussed in the “Risk Factors” section of MARA’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 28, 2024, as amended on May 24, 2024, the “Risk Factors” section of MARA’s Quarterly Report on Form 10-Q filed with the SEC on August 1, 2024, the “Risk Factors” section of MARA’s Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024 and the risks described in other filings that MARA may make from time to time with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and MARA specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required by applicable law. MARA Company Contact: Telephone: 800-804-1690 Email: ir@mara.com
Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE AmgenBEIRUT (AP) — Insurgents’ stunning march across Syria accelerated Saturday with news that they had reached the gates of the capital and that government forces had abandoned the central city of Homs. The government was forced to deny rumors that had fled the country. The loss of Homs is a potentially crippling blow for Assad. It stands at an important intersection between Damascus, the capital, and Syria’s coastal provinces of Latakia and Tartus — the Syrian leader’s base of support and home to a Russian strategic naval base. The pro-government Sham FM news outlet reported that government forces took positions outside Syria’s third-largest city, without elaborating. Rami Abdurrahman who heads the Britain-based Syrian Observatory for Human Rights, said Syrian troops and members of different security agencies have withdrawn from the city, adding that rebels have entered parts of it. The insurgency announced later Saturday that it had taken over Homs. The city’s capture is a major victory for the rebels, who have already seized the cities of and , as well as large parts of the south, in a lightning offensive that began Nov. 27. Analysts said rebel control of Homs would be a game-changer. The rebels’ moves around Damascus, reported by the monitor and a rebel commander, came after the Syrian army withdrew from much of southern part of the country, leaving more areas, including several provincial capitals, under the control of opposition fighters. For the first time in the country’s long-running civil war, the government now has control of only three of 14 provincial capitals: Damascus, Latakia and Tartus. The were among the largest in recent years by opposition factions, led by a group that has its origins in al-Qaida and is considered a terrorist organization by the U.S. and the United Nations. In their push to overthrow Assad’s government, the insurgents, led by the group, or HTS, have met little resistance from the Syrian army. The rapid rebel gains, coupled with the lack of support from Assad’s erstwhile allies, posed the most serious threat to his rule since the start of the war. The U.N.’s special envoy for Syria, Geir Pedersen, on Saturday called for urgent talks in Geneva to ensure an “orderly political transition.” Speaking to reporters at the annual Doha Forum in Qatar, he said the situation in Syria was changing by the minute. Russian Foreign Minister Sergey Lavrov, whose country is Assad’s chief international backer, said he feels “sorry for the Syrian people.” In Damascus, people rushed to stock up on supplies. Thousands went to Syria’s border with Lebanon, trying to leave the country. Many shops in the capital were shuttered, a resident told The Associated Press, and those still open ran out of staples such as sugar. Some were selling items at three times the normal price. “The situation is very strange. We are not used to that,” the resident said, insisting on anonymity, fearing retributions. “People are worried whether there will be a battle (in Damascus) or not.” It was the first time that opposition forces reached the outskirts of Damascus since 2018, when Syrian troops recaptured the area following a yearslong siege. The U.N. said it was moving noncritical staff outside the country as a precaution. Assad’s status Syria’s state media denied social media rumors that saying he is performing his duties in Damascus. He has had little, if any, help from his allies. Russia, is busy with its . Lebanon’s Hezbollah, which at one point sent thousands of fighters to shore up Assad’s forces, has been weakened by a yearlong conflict with Israel. Iran has seen its proxies across the region degraded by regular Israeli airstrikes. U.S. President-elect Donald on social media that that the United States should avoid engaging militarily in Syria. Pedersen said a date for talks in Geneva on the implementation a U.N. resolution, adopted in 2015, and calling for a Syrian-led political process, would be announced later. The resolution calls for the establishment of a transitional governing body, followed by the drafting of a new constitution and ending with U.N.-supervised elections. Later Saturday, foreign ministers and senior diplomats from eight key countries, including Saudi Arabia, Russia, Egypt, Turkey and Iran, along with Pederson, gathered on the sidelines of the Doha Summit to discuss the situation in Syria. In a statement issued late Saturday, the participants affirmed their support for a political solution to the Syrian crisis “that would lead to the end of military activity and protect civilians.” They also agreed on the importance of strengthening international efforts to increase aid to the Syrian people. The insurgents’ march Rami Abdurrahman, who heads the Britain-based Syrian Observatory for Human Rights, an opposition war monitor, said insurgents were in the Damascus suburbs of Maadamiyah, Jaramana and Daraya. Opposition fighters were marching toward the Damascus suburb of Harasta, he added. A commander with the insurgents, Hassan Abdul-Ghani, posted on the Telegram messaging app that opposition forces had begun the “final stage” of their offensive by encircling Damascus. HTS controls much of northwest Syria and in 2017 set up a “salvation government” to run day-to-day affairs in the region. In recent years, has sought to remake the group’s image, cutting ties with al-Qaida, ditching hard-line officials and vowing to embrace pluralism and religious tolerance. The shock offensive began Nov. 27, during which gunmen captured the northern city of Aleppo, Syria’s largest, and the , the country’s fourth largest city. Opposition activists said Saturday that a day earlier, insurgents entered Palmyra, which is home to invaluable archaeological sites had been in government hands since being taken from the Islamic State group in 2017. To the south, Syrian troops left much of the province of Quneitra including the main Baath City, activists said. Syrian Observatory said government troops have withdrawn from much of the two southern provinces. The Syrian army said in a statement that it carried out redeployment and repositioning in Sweida and Daraa after its checkpoints came under attack by “terrorists.” The army said it was setting up a “strong and coherent defensive and security belt in the area,” apparently to defend Damascus from the south. The Syrian government has referred to opposition gunmen as terrorists since conflict broke out in March 2011. Diplomacy in Doha The foreign ministers of Iran, Russia and Turkey, meeting in Qatar, called for an end to the hostilities. Turkey is a main backer of the rebels. Qatar’s top diplomat, Sheikh Mohammed bin Abdulrahman Al Thani, criticized Assad for failing to take advantage of the lull in fighting in recent years to address the country’s underlying problems. “Assad didn’t seize this opportunity to start engaging and restoring his relationship with his people,” he said. Sheikh Mohammed said he was surprised by how quickly the rebels have advanced and said there is a real threat to Syria’s “territorial integrity.” He said the war could “damage and destroy what is left if there is no sense of urgency” to start a political process. ____ Karam reported from London. Associated Press writers Albert Aji in Damascus, Syria; Qassim Abdul-Zahra in Baghdad; Josef Federman and Victoria Eastwood in Doha, Qatar; and Ellen Knickmeyer in Washington contributed to this report. Bassem Mroue And Zeina Karam, The Associated Press
THERE has been a major injury update over Detroit Lions superstar Aidan Hutchinson. The 24-year-old suffered a horror broken tibia and fibula in NFL Week 6 against the Dallas Cowboys . The defensive end was carted off the field in agony, as both teams and shocked fans at the AT&T Stadium watched on. He was rushed into emergency surgery, where they repaired and restructured his fractured leg. It was understood the edge rusher was set to miss the rest of the 2024-25 campaign. But there are now hopes he could make a shock return THIS season, against all the odds. READ MORE ON THE LIONS The Lions have gone on to reach an incredible 12-1 record on the year. That included a dramatic 34-31 win over the Green Bay Packers on Thursday Night Football . Their amazing season comes despite the early loss of the Defensive Player of the Year candidate. But according to ESPN and Amazon Prime sources, he could still make the Super Bowl if Detroit reach it. Most read in American Football "Sources close to Aidan Hutchinson believe the Lions standout defensive end will have a realistic chance to return for the Super Bowl if Detroit advances that far," said insider Adam Shefter. "One source went so far as to tell ESPN that, knowing Hutchinson and his injury, it would be more surprising if he did not make it back for a potential Super Bowl appearance than if he did." Meanwhile, Amazon presenter Albert Breer gave a further update on Hutchinson's status. "One other guy the defense could be getting back is Aidan Hutchinson," he said on Thursday's Lions-Packers broadcast. "He is already started running in a pool and walking without crutches. "He has been in the Lions building every day. 1. Andy Reid - Chiefs - $20 million 2. Sean Payton - Broncos - $18 million =3. Mike Tomlin - Steelers - $16 million =3. Jim Harbaugh - Chargers - $16 million 5. Sean McVay - Rams - $15 million 6. Kyle Shanahan - 49ers - $14 million 7. John Harbaugh - Ravens - $12 million =8. Dan Campbell - Lions - $11 million =8. Sean McDermott - Bills - $11 million 10. Mike MacDonald - Seahawks - $10 million "The expectation is, if they make it to the Super Bowl, Hutchinson will be in uniform." Fans had a mixed reaction to the news, with many sceptical about his injury latest. One said: "Getting a little ahead of ourselves there." Another added: "I really believe they are going to go to the SB...too much fanfare." A third roared: "Let's gooooo!" Read More on The US Sun The Lions sit in first in the NFC North and clinched their playoff spot with the win over the Packers. They are favorites with some bookmakers to win the Super Bowl, alongside the Kansas City Chiefs .Cousins Properties Announces Pricing of Senior Notes Offering
Opinion: Dublin's North inner city's issues must be resolved at the root cause once and for allThe Yankees are hopeful they can re-sign Juan Soto, but as the sweepstakes for the superstar outfielder begin to come to a close, they’re also keeping other doors open to improve their roster. Backup plans are emerging with a Soto decision expected to be made within the next few days, if not during next week’s Winter Meetings in Dallas. The Yankees are interested in both infielder Willy Adames and starting pitcher Max Fried, both top pieces on the free agent market in the tier right below Soto. Mark Feinsand of MLB.com reported Wednesday evening about Adames being a possibility for the Yankees. Adames has been linked to the Yankees previously this offseason as a potential solution to their infield questions this winter. Broadcaster Michael Kay shared that the Yankees recently had a productive Zoom call with Fried on The Michael Kay Show on Wednesday as well. The Yankees could sign Adames to play shortstop and shift Anthony Volpe over to second base, keeping Jazz Chisholm Jr. at third, Fiensand wrote. The other option there would be to move Adames over to third. The free agent prefers to stay at shortstop, but a position change is something he’s willing to do if the situation and dollars are right. If Adames went to third, the Yankees would then put Chisholm at second or even center field. He played up the middle with the Marlins before the Yankees acquired Chisholm at this past summer’s trade deadline. Adames, 29, is coming off a career year with the Brewers, a season in which he set new career-highs with 161 games played, 32 home runs, 112 RBI and 21 stolen bases. Yankees fans will remember Adames from his first four years in MLB, back when he played for the division-rival Rays. Adames is also known for his quality defense, meaning he’ll perform well at shortstop or be capable of sliding over to a new spot on the infield. Fried, 30, is entering his ninth big-league season after eight years with the Braves. He posted a 3.25 ERA over 29 starts in 2024, making his second All-Star Game. Since 2020, Fried is 54-25 with a 2.81 ERA across 112 starts. The left-hander is elite when it comes to keeping the ball on the ground and inducing weak contact. “The Yankees had a 90 minute Zoom call with Max Fried yesterday,” Kay said on Wednesday, “and it supposedly went very well. All the usual suspects were on the Zoom call. ... Somebody who’s on the Fried side said that Max really, really liked them and apparently they’re going to have another meeting as well.” If the Yankees aren’t able to bring Soto back — competition is steep and contract offers are reportedly already above the $600 million threshold from remaining contenders — they’ll have plenty of money to spend. Either way, the Yankees have flaws they need to address this winter. It’s unclear if Adames, Fried and other expensive free agents could still fit into the Yankees’ offseason budget if the team is able to retain Soto. MORE YANKEES COVERAGE One Yankees free agent admits there hasn’t been a lot of interest in him yet Ex-GM has Yankees trade package that lands them a much-needed first baseman Juan Soto contender is pulling out all the stops to sign him | Are Yankees, Mets in trouble? Yankees voice Michael Kay clashes with Mets announcer on MLB’s new idea Yankees interested in reunion with free agent reliever, but should they be? Thank you for relying on us to provide the journalism you can trust. Please consider supporting us with a subscription. Max Goodman may be reached at mgoodman@njadvancemedia.com .SEOUL, South Korea (AP) — South Korea's embattled President Yoon Suk Yeol avoided an opposition-led attempt to impeach him over his short-lived imposition of martial law , as most ruling party lawmakers boycotted a parliamentary vote Saturday to deny a two-thirds majority needed to suspend his presidential powers. The scrapping of the motion is expected to intensify protests calling for Yoon’s ouster and deepen political chaos in South Korea, with a survey suggesting a majority of South Koreans support the president’s impeachment. Yoon’s martial law declaration drew criticism from his own ruling conservative People Power Party, but the party is also determined to oppose Yoon’s impeachment apparently because it fears losing the presidency to liberals. After the motion fell through, members of the main liberal opposition Democratic Party rallied inside the National Assembly, chanting slogans calling for Yoon's impeachment or resignation. The party's floor leader, Park Chan-dae, said it will soon prepare for a new impeachment motion. Opposition parties could submit a new impeachment motion after a new parliamentary session opens next Wednesday. “We'll surely impeach Yoon Suk Yeol, who is the greatest risk to Republic of Korea,” party leader Lee Jae-myung said. “We'll surely bring back this country to normal before Christmas Day or year's end.” Many experts worry Yoon won’t be able to serve out his remaining 2 1⁄2 years in office. They say some PPP lawmakers could eventually join opposition parties’ efforts to impeach Yoon if public demands for it grow further. The ruling party risks "further public outrage and national confusion if they don’t find a formula fast for Yoon’s departure,” said Duyeon Kim, a senior analyst at the Center for a New American Security in Washington. PPP chair Han Dong-hun said his party will seek Yoon’s “orderly” early exit but didn’t say when he can resign. On Saturday, tens of thousands of people packed several blocks of roads leading to the National Assembly, waving banners, shouting slogans and dancing. Protesters also gathered in front of PPP’s headquarters near the Assembly, shouting for its lawmakers to vote to impeach Yoon. A smaller crowd of Yoon’s supporters, which still seemed to be in the thousands, rallied elsewhere in Seoul, calling the impeachment attempt unconstitutional. Impeaching Yoon required support from 200 of the National Assembly's 300 members. The Democratic Party and five other small opposition parties, which filed the motion, have 192 seats combined. But only three lawmakers from PPP participated in the vote. The motion was scrapped without ballot counting because the number of votes didn’t reach 200. National Assembly Speaker Woo Won Shik called the result “very regrettable” and an embarrassing moment for the country’s democracy. If Yoon is impeached, his powers will be suspended until the Constitutional Court decides whether to remove him from office. If he is removed, an election to replace him must take place within 60 days. Earlier Saturday, Yoon issued an apology over the martial law decree, saying he won’t shirk legal or political responsibility for the declaration and promising not to make another attempt to impose it. He said would leave it to his party to chart a course through the country’s political turmoil, “including matters related to my term in office.” “The declaration of this martial law was made out of my desperation. But in the course of its implementation, it caused anxiety and inconveniences to the public. I feel very sorry over that and truly apologize to the people who must have been shocked a lot,” Yoon said. Since taking office in 2022, Yoon has struggled to push his agenda through an opposition-controlled parliament and grappled with low approval ratings amid scandals involving himself and his wife. In his martial law announcement on Tuesday night, Yoon called parliament a “den of criminals” bogging down state affairs and vowed to eliminate “shameless North Korea followers and anti-state forces.” The declaration of martial law was the first of its kind in more than 40 years in South Korea. The turmoil has paralyzed South Korean politics and sparked alarm among key diplomatic partners like the U.S. and Japan. “Yoon’s credibility overseas has been undermined by declaring martial law, so he won’t be able to exercise leadership in his foreign policies especially when his days are numbered,” Kim, the analyst, said. “Its government bureaucracy will need to continue business as usual for existing alliance and foreign policy initiatives as best it can because there is a lot of important work to do globally.” Tuesday night saw special forces troops encircling the parliament building and army helicopters hovering over it, but the military withdrew after the National Assembly unanimously voted to overturn the decree, forcing Yoon to lift it before daybreak Wednesday. Eighteen lawmakers from the ruling party voted to reject Yoon’s martial law decree along with opposition lawmakers. PPP later decided to oppose Yoon's impeachment motion. Yoon’s speech fueled speculation that he and his party may push for a constitutional amendment to shorten his term, instead of accepting impeachment, as a way to ease public anger over the marital law and facilitate Yoon’s early exit from office. Lee told reporters that Yoon’s speech was “greatly disappointing” and that the only way forward is his immediate resignation or impeachment. His party called Yoon’s martial law “unconstitutional, illegal rebellion or coup.” Lawmakers on Saturday first voted on a bill appointing a special prosecutor to investigate stock price manipulation allegations surrounding Yoon’s wife. On Friday, Han, who criticized Yoon’s martial law declaration, said he had received intelligence that during the brief period of martial law Yoon ordered the country’s defense counterintelligence commander to arrest unspecified key politicians based on accusations of “anti-state activities.” Hong Jang-won, first deputy director of South Korea’s spy agency, told lawmakers Friday that Yoon had ordered him to help the defense counterintelligence unit to detain key politicians including Han, Lee and Woo. The Defense Ministry said Friday it suspended three military commanders including the head of the defense counterintelligence unit over their involvement in enforcing martial law. Vice Defense Minister Kim Seon Ho has told parliament that Defense Minister Kim Yong Hyun ordered the deployment of troops to the National Assembly. Opposition parties accused Kim of recommending to Yoon to enforce martial law. Kim Yong Hyun resigned Thursday, and prosecutors imposed an overseas travel ban on him.
US stocks surge to records, shrugging off upheaval in South Korea, FranceAP News Summary at 3:02 p.m. EST
ATLANTA — The Lakers’ four-game road trip, which ended with a disheartening overtime loss to the Atlanta Hawks on Friday , lasted eight days if you count the days they flew out of and back to Los Angeles on the front and back ends of the trip. But considering they were in Southern California for just a few days after their Nov. 26 road loss to the Phoenix Suns and Nov. 27 road win over the San Antonio Spurs – flying back to L.A. Thanksgiving ahead of their Nov. 29 home loss to the Oklahoma City Thunder before flying to Salt Lake City the afternoon of Nov. 30 – the trip felt longer. “It was a two-week road trip, let’s be honest,” coach JJ Redick said Friday night. “It was a two-week road trip.” And the nature of how the last two weeks have gone for the Lakers added to their road weariness. The loss to the Hawks was their third straight defeat, including their losses to the Minnesota Timberwolves and Miami Heat by a combined 70 points, and their seventh loss in nine games going back to the Nov. 21 home loss to the Orlando Magic , the start of another three-game losing streak. While Friday’s loss continued their losing streak, they played with significantly more energy and effort compared to their losses earlier in the week. “Based off the last couple games that we played, Minnesota and Miami, it’s a good bounce back for us,” Anthony Davis said. “Just some of the defensive communication we messed up a little bit [on Friday night]. As far as the carryover, it was better.” When asked what it’ll take for the Lakers, who won their first three games of the season and were 10-4 before their recent skid, to get back over the hump, LeBron James pointed to the players the team has been without. Austin Reaves missed the entire road trip because of a bruised left pelvis suffered Nov. 29 against the Thunder. “With Austin, the movement piece and the thrust, his ability to get in the paint, his ability to, for the most part, make quick decisions,” Redick said. “In some ways, he’s like a connector for our offense, but he’s also a scorer and a playmaker. So you can have connectors that aren’t necessarily players that can do what Austin does in terms of creating offense. He does both. And also, he’s highly competitive and he brings that juice every night.” Backup center Jaxson Hayes has been sidelined 12 of the last 13 games because of right ankle injuries, and isn’t expected to be reevaluated until this upcoming week. Christian Wood (offseason left knee surgery) and Jarred Vanderbilt (offseason feet surgery recovery) have yet to play this season. The Lakers announced that Vanderbilt is expected to return in early January . Wood’s status isn’t as clear. “I don’t know as far as what will get us over the hump,” James said. “We just gotta just not drown. Don’t drown and we’ll be all right.” Or as Davis put it: “There’s no cavalry. No one [feels] sorry for us. We can’t feel sorry for ourselves. Just gotta continue to put our head down and grind and work.” The Lakers will host the Portland Trail Blazers on Sunday at Crytpo.com Arena. Related Articles After that, they’ll get a rare four-day break off of games before playing the Minnesota Timberwolves on Friday in Minneapolis. “That break, if you call it a break, for three, four days, we have to use that for our minds, for our bodies, for clean up,” Redick said. “It’ll be a good opportunity for us.” When : 6:30 p.m. Sunday Where : Crypto.com Arena TV/radio : Spectrum SportsNet/710 AMDonald Trump criticized former President Barack Obama while wading into the ongoing Syria conflict on Saturday, saying the U.S. should not get involved nor should it have ever inserted itself in the matter. In keeping with his isolationist foreign policy, the president-elect wrote on Truth Social that the United States “should have nothing to do with” the situation in Syria – where rebels are currently trying to take over the capital in an attempt to overthrow President Bashar al-Assad’s government. “THIS IS NOT OUR FIGHT. LET IT PLAY OUT. DO NOT GET INVOLVED!” Trump wrote. Yet at the same time, Trump blamed Obama for failing to intervene in the conflict in 2013 when the Russia-backed government used chemical weapons as a form of attack – something Obama initially said was the “red line” that would move the U.S. to get involved. “This is where former President Obama refused to honor his commitment of protecting the RED LINE IN THE SAND, and all hell broke out, with Russia stepping in,” Trump wrote. Russia, an ally of al-Assad, intervened in the Syrian conflict years ago. However, Trump said due to the current status of the Ukraine–Russia conflict, Moscow cannot pivot its attention this time. “Opposition fighters in Syria, in an unprecedented move, have totally taken over numerous cities, in a highly coordinated offensive, and are now on the outskirts of Damascus, obviously preparing to make a very big move toward taking out Assad,” Trump wrote. “Russia, because they are so tied up in Ukraine, and with the loss there of over 600,000 soldiers, seems incapable of stopping this literal march through Syria, a country they have protected for years.” The president-elect said there was “never much of a benefit” in Syria for Russia “other than to make Obama look really stupid.” “In any event, Syria is a mess, but is not our friend, & THE UNITED STATES SHOULD HAVE NOTHING TO DO WITH IT. THIS IS NOT OUR FIGHT. LET IT PLAY OUT. DO NOT GET INVOLVED!” he added. Trump’s comments came as he was in Paris meeting with Ukrainian President Volodymyr Zelensky and French President Emmanuel Macron in his first return to the world stage since clinching victory in the election. The conflict in Syria has been going on since 2011. The government, led by al-Assad, has been a central part of the situation having used brutality against peaceful protesters during the Arab Spring. Since then, the Syrian government has relied on its allyship with Russia, Iran, Hezbollah and others to stay in power. However, those allies, much like Russia, have had their attentions diverted by other crises, giving insurgents an opportunity to push forward in the hopes of unseating al-Assad. Over the last week, conflict has escalated in the country, with rebels beginning to seize much of the northwest territory in an attempt to oust al-Assad. So far, insurgents, led by the Islamist group Hayat Tahrir al-Sham (HTS), have captured land in the city of Aleppo and several Damascus suburbs – marking the first time opposition forces have reached the outskirts of the capital since 2018. The Syrian army has reportedly withdrawn from several Damascus suburbs signalling that al-Assad is losing control over parts of the country. Under Trump, who will return to the White House in a little over a month, it seems unlikely the U.S. will get involved. The president-elect, and his allies, have taken an isolationist approach to foreign conflicts, believing the U.S. should not get involved unless it has a direct interest in it.
Kash Patel: The die-hard loyalist
Dynavax to Present at the 7th Annual Evercore HealthCONx Conference
NoneNoneNone
Riding hot stretch, Grizzlies out to avenge losses to Nets
One Piece Chapter 1133: Here’s release date, time, spoilers and where to read
Indiana aims to run its winning streak to five games Friday night when Nebraska welcomes the Hoosiers to Lincoln, Neb. Indiana (8-2, 1-0 Big Ten) has lost the past three meetings with Nebraska after winning seven straight. The Hoosiers are led by center Oumar Ballo, a transfer from Arizona who averages 13.2 points and 9.1 rebounds per game, and forward Malik Reneau (team-best 15.5 points and 6.4 rebounds). Reneau, according to Indiana, is one of five major-conference players to average at least 10 points per game with a field goal percentage of at least 60 and 80 percent from the free-throw line. Off Indiana's 82-67 home win over Minnesota on Monday, head coach Mike Woodson said there are things to work on going forward. "When you get a team down 15, 20 points, you got to remember how you got them down and continue to do the same things that got you the lead," said Woodson, "and I don't think we did that coming down the stretch." Nebraska's best win this season was over then-No. 14 Creighton in an in-state battle last month. But the Cornhuskers (6-2, 0-1) haven't played a very difficult schedule, and were blown out 89-52 by current No. 21 Michigan State on the road last weekend. The Spartans became the first team in 25 games to make more than 50 percent of their shots against Nebraska, so improved defense will be key for the Huskers. Nebraska was also outrebounded 48-19. "That hadn't been us all year, and that was the disappointing thing," coach Fred Hoiberg said. "The physicality of the game in this league ... we're going to see it every night. I've been pleased with how they've responded, but we'll see how they step up to the challenge Friday night." If Nebraska can turn things around on offense, it is 38-2 under Hoiberg when scoring at least 80 points, including 4-0 this season. Brice Williams is Nebraska's leading scorer at 17.5 points per game. Connor Essegian adds 13.0 ppg and shoots 42.6 percent from 3-point range. --Field Level Media
Personal Cloud Market Future Scope, Size, Share, Growing Trends, Opportunities, Key Segments And Forecast To 2028 12-12-2024 10:18 PM CET | Business, Economy, Finances, Banking & Insurance Press release from: ABNewswire Google (US), Microsoft (US), Apple (US), Dropbox (US), AWS (US), Box (US), Seagate Technology (US), Western Digital (US), Synchronoss (US), Egnyte (US), BUFFALO Technology (Japan), Funambol (US), SugarSync (US), ElephantDrive (US), Cloudike (US), SpiderOa Personal Cloud Market by Type (Online, NAS Device, Server Device), User Type (Enterprise, Consumer), Hosting Type (Provider, User/Self-hosting), Revenue Type (Direct, Indirect), Vertical (IT & ITeS, BFSI, Telecommunications) and Region - Global Forecast to 2028. The global personal cloud market [ https://www.marketsandmarkets.com/Market-Reports/personal-cloud-market-821.html?utm_campaign=personalcloudmarket&utm_source=abnewswire.com&utm_medium=paidpr ] is projected to expand from USD 24.7 billion in 2023 to USD 57.7 billion by 2028, registering a compound annual growth rate (CAGR) of 18.5% during the forecast period. Personal clouds provide individuals with a virtual storage and computing environment, enabling them to store, manage, and access their digital data and applications via the internet. Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=821 [ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=821&utm_campaign=personalcloudmarket&utm_source=abnewswire.com&utm_medium=paidpr ] One of the driving factors behind the surge in the personal cloud market is the ubiquity of smartphones and connected devices. With the increased mobile device usage, consumers are seeking solutions that transcend the limitations of device-specific storage. Moreover, personal cloud services offer a centralized repository, allowing users to effortlessly synchronize and manage their data, creating a seamless and unified experience across various devices. Additionally, In the competitive realm of personal cloud market, innovation is a driving force. Key players in the market continually strive to enhance user experience by introducing intuitive interfaces, leveraging AI for organization and search capabilities, and integrating seamlessly with popular applications. These innovations not only attract new users but also contribute to user retention in an environment where expectations are constantly evolving. By User Type, the enterprises segment is expected to capture the highest CAGR during the forecast period. The user type segment of the personal cloud market is segmented into enterprises and consumers. The enterprises segment is estimated to hold the highest CAGR during the forecasted period. The enterprise user type plays a crucial role in the personal cloud market, contributing to the demand for advanced features, robust security measures, and scalable solutions that cater to the specific demands of businesses. Unlike individual consumers, enterprises often require cloud services that facilitate collaboration, data management, and secure access for multiple users within a corporate environment. The role of the enterprise user type extends beyond basic storage needs, influencing the development of features such as advanced collaboration tools, administrative controls, and comprehensive security protocols. A real-world example illustrating the impact of enterprise user types is the adoption of Microsoft OneDrive for Business. Microsoft has strategically positioned OneDrive for Business as part of its Microsoft 365 suite, catering specifically to the needs of enterprises. This service integrates seamlessly with other productivity tools, such as Microsoft Teams and SharePoint, providing businesses with a comprehensive ecosystem for file storage, collaboration, and communication. Enterprise-focused features, including advanced security measures, compliance tools, and centralized administrative controls, demonstrate how personal cloud providers tailor their offerings to meet the demands of large organizations. Additionally, the enterprise user type influences pricing models within the personal cloud market. Many providers offer business-oriented plans with tiered pricing by the number of users, storage requirements, and additional enterprise-grade features. This approach allows personal cloud service providers to address the scalability and customization needs of enterprises, aligning their offerings with the requirements of larger organizations that often operate on a different scale compared to individual consumers. As the trend towards remote work and digital collaboration continues, the role of the enterprise user type will likely grow in significance, shaping the direction of innovation and competition in the personal cloud market. Based on enterprises, the large enterprises segment is expected to account for the largest market share during the forecast period. The personal cloud market, by enterprises, is segmented into SMEs and large enterprises. It is expected that during the forecast period, the large enterprises segment is expected to hold the largest market size and share in the personal cloud market. Large enterprises wield significant influence in the personal cloud market, driving demand for advanced features, enterprise-grade security, and scalable solutions tailored to the complexities of expansive organizational structures. Unlike individual consumers or SMEs, large enterprises operate on a massive scale, necessitating personal cloud services that can accommodate extensive data storage, sophisticated collaboration tools, and stringent security measures. The role of large enterprises in shaping the personal cloud market is characterized by their capacity to set high standards for performance, security, and customization. A compelling example illustrating the impact of large enterprises on the personal cloud market is Amazon Web Services (AWS), which offers a comprehensive set of cloud services, including Amazon S3 for scalable object storage. Large enterprises leverage AWS for their cloud storage needs, benefiting from its reliability, scalability, and integration with a wide range of additional services. AWS caters to the diverse requirements of large enterprises by providing customizable solutions that align with their extensive computing and storage demands, effectively setting a benchmark for the industry. Moreover, the role of large enterprises extends to influencing the development of cutting-edge technologies within the personal cloud market. As these enterprises adopt emerging technologies like artificial intelligence, machine learning, and advanced analytics, personal cloud providers are compelled to integrate these functionalities into their services. The demand for innovative solutions that enhance data processing, insights generation, and overall efficiency is often driven by the requirements of large enterprises, shaping the trajectory of technological advancements within the personal cloud market. North America is projected to hold the largest market share during the forecast period. By region, North America is projected to hold the most market share in the worldwide personal cloud market in 2023, and this pattern is anticipated to be true over the course of the forecast period. The personal cloud market in North America has emerged as a dynamic and influential force, reshaping the way individuals manage and access their digital content. The US and Canada are the major contributors, as most of the major companies of the personal cloud market are based in these countries. The region's strong technological infrastructure and high levels of digital adoption have fueled the growth of personal cloud services, which encompass storage, synchronization, and sharing solutions for personal data. With the increasing reliance on smartphones, tablets, and other connected devices, users in North America are seeking seamless and secure ways to store and access their photos, videos, documents, and other files. Personal cloud services provide a convenient and user-friendly platform for individuals to store their digital assets remotely, allowing them to retrieve and share data across multiple devices effortlessly. Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=821 [ https://www.marketsandmarkets.com/requestsampleNew.asp?id=821&utm_campaign=personalcloudmarket&utm_source=abnewswire.com&utm_medium=paidpr ] Unique Features in the Personal Cloud Market Personal cloud solutions offer users the convenience of accessing their data and applications from anywhere, on any device, as long as they are connected to the internet. This anytime-anywhere accessibility ensures seamless user experiences and supports a mobile-first lifestyle. Unlike traditional public cloud solutions, personal clouds emphasize greater control over data privacy and security. Many personal cloud platforms allow users to manage encryption settings, access permissions, and data sharing, ensuring their sensitive information remains protected. Personal clouds are increasingly designed to integrate seamlessly with a wide range of smart devices, including smartphones, tablets, smart TVs, and IoT gadgets. This interconnected ecosystem allows users to synchronize data and applications across multiple devices effortlessly. Personal cloud services are highly customizable, enabling users to choose storage plans and features tailored to their specific needs. Additionally, they are scalable, allowing individuals to expand storage capacity as their data requirements grow without significant cost or effort. Many personal cloud solutions provide offline synchronization features, enabling users to access and modify files without an internet connection. Automatic backups ensure that data remains secure and recoverable in case of device failures or accidental deletions. Major Highlights of the Personal Cloud Market With growing concerns about data breaches and privacy, individuals are turning to personal cloud solutions that offer enhanced security features and greater control over data management. Providers are responding by incorporating advanced encryption, multi-factor authentication, and user-controlled access settings. The proliferation of smartphones, tablets, and other mobile devices has fueled the demand for personal clouds. These solutions allow users to synchronize and access their data seamlessly across multiple devices, catering to the needs of an increasingly mobile and connected population. As IoT devices become more prevalent in households, personal clouds are evolving to support seamless integration with smart home systems. This capability enables users to manage and store data generated by IoT devices efficiently, enhancing convenience and functionality. Artificial intelligence is playing a transformative role in the personal cloud market. AI-driven features like smart data categorization, predictive storage optimization, and enhanced search capabilities are making personal cloud platforms more intuitive and user-friendly. Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=821 [ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=821&utm_campaign=personalcloudmarket&utm_source=abnewswire.com&utm_medium=paidpr ] Top Companies in the Personal Cloud Market Some of the major personal cloud vendors Google (US), Microsoft (US), Apple (US), Dropbox (US), AWS (US), Box (US), Seagate Technology (US), Western Digital (US), Synchronoss (US), Egnyte (US), BUFFALO Technology (Japan), Funambol (US), SugarSync (US), ElephantDrive (US), Cloudike (US), SpiderOak (US), ASUS Cloud (Taiwan), IDrive (US), AT&T (US), and OpenDrive (US). Google Google is a global technology corporation that focuses on internet-related services and goods, including cloud computing, software, hardware, online advertising technologies, and search engines. Along with Amazon, Apple, Meta, and Microsoft, it is regarded as one of the big five companies in the American information technology industry. Google helps solve business problems with cloud technology. Its cloud solutions are present in various industries, such as retail, consumer packaged goods, financial services, healthcare and life sciences, media & entertainment, gaming, telecom, and manufacturing. Google Cloud offers solutions such as data cloud, artificial intelligence (AI), APIs & applications, security, digital transformation, databases, smart analytics, productivity & collaboration, application, and infrastructure modernization. Google offers personal cloud services through its Google Drive platform. Introduced in 2012, Google Drive provides users with cloud storage, file sharing, and collaboration tools. Users can store their documents, photos, and videos in the cloud and access them from different devices with ease. The service integrates with other Google Workspace apps, enhancing productivity and collaboration. Google Drive offers a free storage tier with options to upgrade for additional space, making it accessible to a broad user base. Google's emphasis on integration with its ecosystem and user-friendly features positions Google Drive as a popular choice for personal cloud storage. The platform's reliability, cross-platform compatibility, and continuous updates contribute to its widespread adoption. Though it faces competition from other major players, Google's commitment to innovation and seamless integration keeps it at the forefront of the personal cloud market, catering to the diverse storage and collaboration needs of individuals. Its cloud storage is reliable and secure, which helps in the transition to lower-cost classes and archival storage. Google has its presence in Asia Pacific, North America, Europe, Latin America, and the Middle East & Africa. pCloud pCloud is a file hosting service (also known as cloud storage) for individuals and businesses. It offers features, such as file management, sharing, security, file backup, collaboration, and file versioning. pCloud is compatible with Windows, macOS, Linux, iOS, and Android platforms. It offers 10 GB of free storage with an option to get up to 20 GB through referrals. It helps to backup folders from computer to pCloud safely. It differentiates itself from other vendors in the personal cloud market by offering innovative lifetime plans to its users. pCloud helps SMEs improve business workflow; facilitates file storage, sharing, and collaboration; and reduces operational costs by eliminating the need for local servers. It shares links and invites users to share folders, access, and synchronize. Media Contact Company Name: MarketsandMarkets Trademark Research Private Ltd. Contact Person: Mr. Rohan Salgarkar Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=personal-cloud-market-future-scope-size-share-growing-trends-opportunities-key-segments-and-forecast-to-2028 ] Phone: 18886006441 Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 City: Florida State: Florida Country: United States Website: https://www.marketsandmarkets.com/Market-Reports/personal-cloud-market-821.html This release was published on openPR.
- Previous: f1 esports
- Next:
